| Name | Title | Contact Details |
|---|
We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we`ve rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life`s work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions.
Stat Medical is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical Technology Inc is a Broadview Heights, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Precision Medical is a Matthews, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.